Comparing two doses of lenvatinib for thyroid cancer not helped by iodine
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study compares two doses of lenvatinib (24 mg vs 10 mg per day) to see which works better for people with thyroid cancer that no longer responds to radioactive iodine. It's for those whose cancer is growing or causing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of thyroid cancer called differentiated thyroid cancer (like papillary, follicular, or Hurthle cell).
- Your cancer must be resistant to radioactive iodine (RAI) - meaning RAI didn't work, you can't have it, or you've already had a lot of it.
- You can't have had more than one targeted therapy drug (like sorafenib or cabozantinib) before this trial.
- Your cancer must be causing symptoms or getting worse, and you need to be 18 or older.
- You must be in fairly good health (able to care for yourself, good blood pressure, and normal kidney and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
This study looks at how well different second-line medicines work for people with a type of thyroid cancer that no longer responds to radioactive iodine. It is an observational study, so you continue your regular treatment and the researchers just collect information about your experience.
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.